Corporate News

Novavax (NVAX) Gains Over 46% In 5 Days, To Report Phase 3 NanoFlu Data In Q1

Shares of Novavax Inc. (NVAX) have gained more than 46% over the last 5 trading days, thanks to positive development related to its NanoFlu vaccine.

Novavax is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

More Corporate News